Place de la radiothérapie stéréotaxique dans le cancer du poumon non à petites cellules en oligoprogression [Place of stereotactic radiotherapy in oligoprogressive non-small cell lung cancer]
Fiche du document
1 juin 2022
- doi: 10.53738/REVMED.2022.18.784.1125
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.784.1125
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35647751
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A697396946800
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Cancers Néoplasme malin Tumeurs malignesCiter ce document
G. Bernard et al., « Place de la radiothérapie stéréotaxique dans le cancer du poumon non à petites cellules en oligoprogression [Place of stereotactic radiotherapy in oligoprogressive non-small cell lung cancer] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.784.1125
Métriques
Partage / Export
Résumé
This review of the literature provides an overview of the combination of stereotactic radiotherapy (SBRT) with immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) in oligo-progressive non-small cell lung neoplasia. This combination showed local control of 76-100% and distant response rates of 8-60%. They reported progression-free survival of 2.7-24 months and overall survival of 13.4-41.2 months. All-grade toxicity rates ranged from 0% to 42%, with grade≥3 toxicity ranging from 0% to 14%. The combination of SBRT with ICI or TKIs exhibits a safe profile with high rates of local control with this combination. This could delay the use of a new line of systemic therapy in these patients with often limited therapeutic resources.